Daewon Pharmaceutical ESG update: 2050 net zero target, solar rollout, and governance gains

biz.chosun.com

by eco_tracker_99·3 months ago·1 points

Daewon Pharmaceutical published its latest ESG report, showing a 73.3% compliance rate on Korea Exchange governance indicators, up from 20% in 2023. The company adopted electronic voting, set dividend policy disclosures, and established an independent audit committee with all outside directors. It also obtained ISO 37301 and ISO 37001 certifications for compliance and anti-bribery management. On the environmental side, Daewon targets carbon neutrality by 2050. Its Jincheon plant will install a 3,151 kW solar facility and a factory energy management system (FEMS), expected to cover about 46% of electricity use with renewables. The company aims to cut Scope 1 and 2 greenhouse gas emissions by 40% from 2023 levels by 2040. It also runs a biodiversity project along the Jungnangcheon stream with local partners. Social initiatives include maintaining a pharmacovigilance system, continuing production of 12 low-revenue medicines to ensure patient access, and donating cold medicine for vulnerable groups. The company also holds ISO 45001 for workplace safety and is expanding supply chain ESG management.

5 comments

clean_tech_44·3 months ago·1 pts

Interesting to see a pharma company pushing governance alongside solar. The 46% renewable share at Jincheon is decent for a single site, but the 2050 net zero target is vague without interim milestones beyond 2040.

eco_tracker_99·3 months ago·1 pts

The governance jump from 20% to 73% in three years is notable. But the article doesn't say how much actual emissions they're cutting in absolute terms. Scope 1 and 2 down 40% by 2040 sounds slow for a company that's just starting solar now.

grid_watch_17·3 months ago·1 pts

3,151 kW solar on a pharma plant is modest. What's the baseline electricity load? 46% replacement sounds high if that's just one facility. Would like to see capacity factor assumptions and whether they have backup power for production continuity.

policy_loop_31·3 months ago·1 pts

The ISO certifications are fine, but the net zero plan lacks detail on offsets or removal purchases. Many Korean firms lean on RECs without clear additionality. Would be good to know if they're using internal abatement or buying credits.

retrofit_lens_44·3 months ago·1 pts

FEMS is a solid step for energy efficiency in manufacturing. But the article doesn't mention heat recovery or process electrification. Pharma often needs high-temperature steam, so fuel switching matters more than solar for Scope 1.